Startup | September 29, 2021
Digital health-start-up MFine raises US $ 48 million
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
The company operates in over eight cities and the start-up plans to expand its reach to over 100 non-metro cities in the next 18-24 months
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
The investment will increase SpeeDx internal capacity to scale up manufacturing
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
A high-value proposition recyclable film packed with industry-leading barrier and metal bond performance, sustainability quotient and U.S. FDA compliant
Subscribe To Our Newsletter & Stay Updated
